Dexamethasone-eluting stent: an anti-inflammatory approach to inhibit coronary restenosis
Authors:
- Xiaoshun LiuXLXiaoshun Liu
- Ivan De ScheerderISIvan De Scheerder
- Walter DesmetWDWalter Desmet
- 1 September 2004
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 2 (5) , 653-660
Abstract
The long-term efficacy of percutaneous coronary interventions is still hampered by restenosis. Restenosis is the result of a complex pathophysiological process, which is thought to be caused by an exaggerated healing response induced by the vascular injury caused by the percutaneous coronary interventions and the implantation of a foreign body (the stent). There is increasing evidence that inflammation plays an important role in the initiation and development of neointimal hyperplasia and subsequent restenosis. Dexamethasone (Decadron, Merck Sharpe and Dohme Ltd) is a glucocorticoid with well-known potent anti-inflammatory and antiproliferative properties. Early studies using either systemic or local delivery of dexamethasone have shown limited beneficial effects on restenosis. The dexamethasone-eluting stent (Dexamet, Abbott Vascular Devices Ltd) is one of the first generation of drug-eluting stents for local drug delivery to prevent restenosis. Preclinical studies demonstrated that implantation of dexamethasone-loaded coronary stents was safe and had a beneficial effect on stent implantation-related inflammation. A pilot trial suggested a beneficial effect on restenosis. Large randomized trials are underway to confirm these findings. This article reviews the potential role of inflammation in the pathogenesis of restenosis and the efficacy of dexamethasone in the prevention of restenosis.Keywords
This publication has 46 references indexed in Scilit:
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- Inflammation As A Key Event In The Development Of Neointima Following Vascular Balloon InjuryClinical and Experimental Pharmacology and Physiology, 2001
- Elevated Circulating Levels of Monocyte Chemoattractant Protein-1 in Patients With Restenosis After Coronary AngioplastyArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- Monocyte Recruitment and Neointimal Hyperplasia in RabbitsArteriosclerosis, Thrombosis, and Vascular Biology, 1996
- Molecular mechanisms of anti‐inflammatory action of glucocorticoidsBioEssays, 1996
- Local methylprednisolone inhibition of foreign body response to coated intracoronary stentsCoronary Artery Disease, 1996
- Expression of ICAM-1 and VCAM-1 and Monocyte Adherence in Arteries Exposed to Altered Shear StressArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Corticosteroid agents inhibit proliferation of smooth muscle cells from human atherosclerotic arteries in vitroInternational Journal of Cardiology, 1994
- Triphasic sequence of neointimal formation in the cuffed carotid artery of the rabbit.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992
- Poly's lament: the neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune responseImmunology Today, 1992